Annexon Biosciences Inc. (ANNX): Growth-Adjusted P/E Ratio
Annexon, Inc. minimizes late-stage risks by diversifying its development across neurology and ophthalmology. The portfolio is expanding through the blocking of immune proteins for the therapy of rare brain pathologies. Business stability in the US and EU is protected by the international status of medicine. The P/E to growth ratio visualizes the investment attractiveness, where the level of 0.00 is the current value of this metric.
Metric breakdowns and analytics for Annexon, Inc. (ANNX)
- stock price and consensus target price:
- stock exchange capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- earnings and multiples data:
ANNX - Net Profit|Future Profit Annexon, Inc.|ANNX - Price to Earnings Ratio|Market Cap to Projected Earnings Annexon Biosciences Inc.|ANNX - PEG Multiple|EV/EBITDA Multiple Annexon Inc.|ANNX - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Annexon|ANNX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months annexonbio.com|ANNX - Net earnings per share growth this year|Projected earnings per share growth rate for next year Annexon, Inc.
Summary company analytics:Annexon Biosciences, ANNX
Professional capital evaluates Annexon, Inc. (ANNX) through the lens of profit scaling efficiency relative to market value. By analyzing the average PEG ratio, investors compare the P/E multiple with earnings growth rates: a ratio below one signals undervaluation, yet for the biotechnology sector—where clinical trial failure risks persist—such a metric may mask high volatility in the asset's fundamental reliability.
Competing companies
Biogen Inc - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Neurocrine Biosciences Inc NBIX|RGC: Growth-Adjusted P/E Ratio|Axsome Therapeutics - PEG Multiple|Price to Earnings Adjusted for Growth Rate acadia-pharm.com|XENE (Xenon) - Price/Earnings to Growth Multiple|Growth-Adjusted P/E Ratio VKTX|Price/Earnings to Growth Ratio Supernus Pharma|Price to Earnings Adjusted for Growth Rate Catalyst Corp CPRX|Price/Earnings to Growth Ratio Denali Therapeutics (DNLI)|harmonybiosciences.com - Growth-Adjusted P/E Ratio|Biohaven - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio AMLX|Trevi Pharma - PEG Multiple|Growth-Adjusted Market Cap to Net Income Praxis Corp PRAX|Anavex Life Sciences (AVXL) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio CBLL|PRTA (Prothena Corporation plc) - PEG Multiple|Price/Earnings to Growth Multiple Alector Therapeutics (ALEC)|Price/Earnings to Growth Multiple OMER (Omeros Corporation)|Growth-Adjusted Market Cap to Net Income Neurogene Therapeutics|PEG Multiple ACIU (AC Immune)|PEG Multiple voyagertherapeutics.com VYGR|NMRA - Price/Earnings to Growth Ratio|SCLX (Scilex Holding) - Growth-Adjusted P/E Ratio|Tevogen Bio Holdings, Inc. (TVGN) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio ACOG|Price/Earnings to Growth Multiple CGTX|Growth-Adjusted P/E Ratio IKT (inhibikase.com)|Price/Earnings to Growth Ratio Cassava Sciences (SAVA)|assertiotx.com - Growth-Adjusted P/E Ratio|PEG Multiple COYA (Coya Therapeutics)|VistaGen Therapeutics, Inc. (VTGN) - Price to Earnings Adjusted for Growth Rate|OVID: Price/Earnings to Growth Multiple|ABOS - PEG Multiple|CervoMed (CRVO) - Price/Earnings to Growth Ratio|Alterity Therapeutics Limited - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Clene Inc|Price to Earnings Adjusted for Growth Rate PepGen Corp PEPG|PEG Multiple JUNS|PEG Multiple relmada.com (RLMD)|Price/Earnings to Growth Ratio Annovis Bio ANVS|GRCE: Growth-Adjusted P/E Ratio|AIFF - Price/Earnings to Growth Ratio|KLTO (Klotho Neurosciences Inc) - Growth-Adjusted P/E Ratio|NRSN: PEG Multiple|Price to Earnings Adjusted for Growth Rate revivapharma.com (RVPH)|Price/Earnings to Growth Multiple MTVA|Growth-Adjusted P/E Ratio NRXS (NeurAxis Inc.)|Price/Earnings to Growth Ratio Helius Medical (HSDT)|PASG - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Neuphoria Therapeutics NEUP|NERV: Growth-Adjusted P/E Ratio|ATHA: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ADXN (Addex Therapeutics Ltd.)|ALZN: PEG Multiple|CYCN - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Protagenic Therapeutics Inc.|Growth-Adjusted P/E Ratio KTTA (Pasithea)|PEG Multiple CRGT|Price/Earnings to Growth Multiple Avenue Therapeutics Inc. ATXI|Brainstorm Cell Therapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income Cara Therapeutics Inc (CARA)|Chromocell Therapeutics - PEG Multiple|ELYM - PEG Multiple|intracellulartherapies.com (ITCI) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio LBPH|Price/Earnings to Growth Ratio Marinus|Growth-Adjusted P/E Ratio NKGN (NKGen Biotech Corp)|Price/Earnings to Growth Multiple NRBO (NeuroBo Pharmaceuticals)|sagerx.com - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Synaptogenix SNPX|TRVN: Growth-Adjusted P/E Ratio|Vigil Neuro - PEG Multiple|Price to Earnings Adjusted for Growth Rate Anew Medical Inc.|CERE (Cerevel Therapeutics) - Price/Earnings to Growth Multiple
